Customer Publication

Cytoplasmic localization of prostate-specific membrane antigen inhibitors may confer advantages for targeted cancer therapies

Authors: J. Matthias et al.

Journal: Cancer Research (2021)

Institution: Max Planck Institute for Medical Research, Heidelberg

Research Areas: Cytotoxicity

Cell Lines: LNCaP and 22Rv1 (LNCaP - androgen-sensitive human prostate adenocarcinoma cell line; 22Rv1 - prostate carcinoma epiithelial cell line)

Summary: The metastatic, castration-resistant prostate cancer represents a major therapeutic challenge as treatment options are limited to only a few options, such as prostate-specific membrane antigen (PSMA) inhibitors. However, the detailed understanding of the mode of action inside the cells and the internalization mechanism of these molecules are still unknown. In this publication, J. Matthias with colleagues have synthesized a fluorescence-labeled PMSA inhibitors and elucidated their uptake mechanism and fate inside the cell using STED nanoscopy. HoloMonitor M4 was used to evaluate fluorescence molecule cytotoxicity and revealed that they do not affect cell proliferation.

Keywords: HoloMonitor M4, Cell Proliferation

Read the article …

Phase Holographic Imaging PHI AB
Skiffervägen 48
224 78 Lund
+46 46 38 60 80

Phase Holographic Imaging PHI Inc.
265 Franklin Street Suite 1702
Boston, MA 02110
+1 617-963-5150


VAT: SE556542781101

Securities Identification

ISIN: SE0005504636
LEI: 549300JZR79QYESM6296

HoloMonitor® is a registered trademark
Copyright © 2012-2021
Phase Holographic Imaging PHI AB

Phase Holographic Image logo in white

PHI Theme 3.12.2